GSK delivered a clean Q1 beat on April 29 and reaffirmed full-year guidance. The market sold the news hard anyway, dropping the stock 5.6% on the day and 7.7% across the week to $51.40.
The earnings numbers were unambiguous. Adjusted EPS came in at $1.25 against a $1.17 consensus estimate. Sales of $10.22 billion edged past the $10.19 billion forecast. GSK reaffirmed its 2026 guidance of 3%-5% turnover growth and 7%-9% core EPS growth, with a target of £40 billion-plus in sales by 2031. Shingrix, the shingles vaccine, continued to power the specialty medicines segment. Yet weakness in other divisions drew scrutiny on the call, and the stock's failure to hold any of its initial gains underscored how cautious the market has become.
The positioning picture adds important context to that caution. Short interest is genuinely modest — just 0.52% of the free float, down steadily from a peak of around 0.75% in late March and early April when shorts built positions. That build-up has since reversed, with short shares declining from roughly 28.9 million at the start of April to under 20 million by late last week. Borrow conditions are relaxed: availability against outstanding short interest is effectively unlimited, and the cost to borrow is 0.56% — barely above the risk-free rate. With borrow so cheap and plentiful, there is no mechanical short-squeeze pressure in the lending market, and the week's selloff looks driven by real-money outflows rather than positioning extremes.
Options told the most interesting story of the week. By the close on April 29, the put/call ratio had dropped sharply to 0.50 — more than three standard deviations below its 20-day average of 0.55. That kind of collapse in the PCR during a falling tape is unusual. It suggests call buyers stepped in aggressively, either speculating on a post-earnings recovery or rolling into upside structures on the dip. The full-year PCR range runs from 0.38 to 1.40, so 0.50 is still in the bullish half of the distribution. The divergence between a falling stock and rising call demand is the sharpest single-day signal in the data.
The broader factor scorecard reflects the stock's somewhat awkward positioning. The dividend score ranks in the 95th percentile of the universe — a standout number for income-oriented holders. The EV/EBIT ratio ranks in the 77th percentile, and the utilization rank, measuring how tight the borrow pool has become, is also elevated at 77. The PE multiple has compressed about 1.0 point over the past thirty days to 10.4x, while EV/EBITDA has fallen roughly half a point to 14.4x — modest de-ratings that reflect the month's price action rather than any fundamental deterioration. The short score of 47.9 is essentially neutral, consistent with the low short interest reading. Where the scorecard turns less flattering is forward earnings: the 12-month forward EPS growth rank is in the 25th percentile, and EPS surprise ranks 33rd, suggesting the Street does not expect GSK to sustain its current beat cadence.
On the analyst front, the most recent available change of significance is a Barclays downgrade to Underweight from Equal-Weight, filed in January 2026. The move to a below-consensus stance from one of the stock's London-based coverage banks is worth noting in context — the stock is now trading at $51.40, below the Goldman Sachs initiation target of $47.00 set in mid-2024. That initiation target is now stale, and the mean consensus target in the data at $42.74 appears to reflect even older vintage data; investors should treat those numbers with caution rather than as live market estimates. The broader direction of analyst travel since mid-2024 has been a grind lower on conviction — multiple firms moving from Buy to Hold or Neutral — punctuated by Jefferies' brief return to Buy in October 2025.
Institutional ownership provides a degree of structural support. BlackRock recently added 41.3 million shares, bringing its position to 9.9% of the company. FMR (Fidelity) added 47.2 million shares to reach 4.7%. Wellington Management added 21.8 million shares. Those are material inflows from names that typically act on multi-year views, suggesting the long-duration case for the pipeline and dividend yield remains intact for large passive and active allocators even as shorter-term holders take profits. GSK's next event is a Q2 update scheduled for May 6 — a quick turnaround that will test whether the Q1 beat can hold in context or whether the April 29 reaction has already set the tone for how the market wants to trade the name into the summer.
See the live data behind this article on ORTEX.
Open GSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
